检索结果-南通市图书馆

Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer

World Journal of Gastrointestinal Surgery 2009年第1期1卷 30-37页

作者： Joerg Theisen Bernd Krause christian peschel Roland Schmid Hans Geinitz Helmut Friess Department of Surgery Klinikum rechts der IsarTU Muenchen Department of Nuclear Medicine Klinikum rechts der IsarTU Muenchen Department of Oncology Klinikum rechts der IsarTU Muenchen Department of Gastroenterology Klinikum rechts der IsarTU Muenchen Department of Radiation Oncology Klinikum rechts der IsarTU Muenchen

Since the introduction of multimodal therapy regimens,the prognosis of esophageal cancer has *** is undoubtedly true for patients with surgically resected tumors in the case of a response to neoadjuvant chemotherapy or *** conclusions can be drawn from this regarding the indication for perioperative therapies,the radicality of surgery,or the surgical ***,most of the current research in this f ield is aimed at the early identif ication of this subset of patients,at the beginning of,or even before,neoadjuvant *** staging tools have failed to predict responses to neoadjuvant ***,molecular imaging methods,*** emission tomography(PET)-scans,have shown promising results in the early selection of responders and non-responders during the course of neoadjuvant therapy,allowing physicians to alter the treatment plan *** more desirable is the identif ication of potential responders before the start of neoadjuvant *** molecular data on biopsy specimens demonstrate the possibility of early response prediction in these *** present the current knowledge on response evaluation and prediction in esophageal cancer and draw conclusions for future clinical practice and studies in this review.

关键词： Esophageal cancer Response prediction Individualized therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [<sup>18</sup>F]Fluorothymidine-PET

引用

Advances in Molecular Imaging 2015年第2期5卷 17-28页

作者： Nicolas Graf Zhoulei Li Ken Herrmann Michaela Aichler Jolanta Slawska Axel Walch christian peschel Markus Schwaiger Andreas K. Buck Tobias Dechow Ulrich Keller III. Medical Department of Hematology and Medical Oncology Technische Universitat München Munich Germany Department of Nuclear Medicine Technische Universitat München Munich Germany Department of Nuclear Medicine Universitat Sklinikum Würzburg Würzburg Germany Institute of Pathology—Analytical Pathology Helmholtz Zentrum München Neuherberg Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Heidelberg Germany

Background: Inhibition of the lymphoma surface antigen CD40 by the antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various lymphoma subtypes. In this preclinical in vivo study we examined the suitability of positron emission tomography (PET) using the thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine (FLT) for early response assessment upon HCD122 treatment in diffuse large B cell lymphoma (DLBCL). Methods: Immunodeficient mice bearing human DLBCL xenografts (SU-DHL-4) received weekly intraperitoneal injections of HCD122. Tumor growth was followed up until Day 14. Molecular imaging with FLT-PET was performed before (Day 0) and after start of therapy (Day 2 and Day 7). On Day 14 lymphoma xenografts were explanted for immunohistochemical analysis to correlate PET findings with CD40 surface expression on tumor tissue. Results: Treatment with HCD122 significantly delayed tumor growth resulting in a tumor growth inhibition of 45% on Day 14. Significant reduction of tumor-to-background ratio (TBR) of FLT-PET was seen in treated animals on Day 7 and preceded change of tumor volume, thus predicting therapy response to HCD122. Immunohistochemical analysis of xenografts revealed significantly higher CD40 expression on treated than on untreated tissue. Moreover, we found a significant correlation between CD40 expression and FLT-PET response for xenograft tumor treated with HCD122. Conclusions: Treatment of DLBCL with the antagonistic CD40 antibody HCD122 can be monitored with FLT-PET as early as seven days after commencement of therapy and seems to increase CD40 expression on tumor tissue.

关键词： CD40 Antibody FLT-PET Lymphoma Therapy Monitoring

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：